The Fierce 15 has arrived

It's that time of year again. Our sister publication FierceBiotech has released its pick of the top 15 companies at the forefront of drug development. Biotech is a risky field and while not all of these companies will be as successful as they hope to be, you can bet at least a few on the list will make headlines as future acquisition targets or IPO-stage companies with commercial opportunities to pursue. Click here to see the 2008 Fierce 15 winners. List

Suggested Articles

Compass' CD137 agonist cleared large tumors in mice that other I-O agents had failed to treat. It's advancing the drug into phase 1 human trials.

UPMC researchers are planning clinical trials of a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity.

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.